BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3550609)

  • 1. [Pharmacokinetics and metabolism of anthracyclines in man].
    Robert J
    Pathol Biol (Paris); 1987 Jan; 35(1):27-30. PubMed ID: 3550609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and metabolism of anthracyclines.
    Robert J; Gianni L
    Cancer Surv; 1993; 17():219-52. PubMed ID: 8137342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin.
    Bains OS; Karkling MJ; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2009 May; 37(5):1107-14. PubMed ID: 19204081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of daunorubicinol in the rabbit: comparison with daunorubicin.
    Maniez-Devos DM; Baurain R; Trouet A; Lesne M
    J Pharmacol; 1986; 17(1):14-20. PubMed ID: 3713197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin and daunorubicin plasmatic, hepatic and renal disposition in the rabbit with or without enterohepatic circulation.
    Maniez-Devos DM; Baurain R; Lesne M; Trouet A
    J Pharmacol; 1986; 17(1):1-13. PubMed ID: 3713196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
    Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin.
    Bains OS; Takahashi RH; Pfeifer TA; Grigliatti TA; Reid RE; Riggs KW
    Drug Metab Dispos; 2008 May; 36(5):904-10. PubMed ID: 18276838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
    Zenebergh A; Baurain R; Trouet A
    Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent data on anthracyclines].
    Marty M; Espie M; Gisselbrecht C; Lagier G
    Pathol Biol (Paris); 1987 Jan; 35(1):5-10. PubMed ID: 3550613
    [No Abstract]   [Full Text] [Related]  

  • 13. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
    Ando S; Sasada M; Uchino H; Kagawa D; Ueda T; Nakamura T
    Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2343-55. PubMed ID: 3471823
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic and cytotoxic studies of pegylated liposomal daunorubicin.
    Song H; Zhang J; Han Z; Zhang X; Li Z; Zhang L; Fu M; Lin C; Ma J
    Cancer Chemother Pharmacol; 2006 May; 57(5):591-8. PubMed ID: 16133530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-binding characteristics of aclarubicin as compared with daunorubicin and doxorubicin.
    Ando S; Kamiya K; Yoshimura T; Tsutani H; Ueda T; Uchida M; Nakamura T; Uchino H
    Anticancer Res; 1988; 8(3):409-15. PubMed ID: 3164610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas].
    Robert J; Vrignaud P; Iliadis A; Eghbali H; Hoerni B
    Nouv Rev Fr Hematol (1978); 1983; 25(2):91-5. PubMed ID: 6866757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
    Jaenke RS; Deprez-DeCampeneere D; Trouet A
    Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin plasma and blood pharmacokinetics after single i.v. bolus in advanced cancer patients.
    Camaggi CM; Strocchi E; Martoni A; Angelelli B; Comparsi R; Pannuti F
    Drugs Exp Clin Res; 1985; 11(4):285-94. PubMed ID: 3869807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxorubicin pharmacokinetics in the rabbit.
    Maniez-Devos DM; Baurain R; Trouet A; Lesne M
    J Pharmacol; 1985; 16(2):159-69. PubMed ID: 4058012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intracellular accumulation, retention, and distribution of anthracyclines in a multidrug-resistant variant K562r].
    Hu X; Chen WY
    Zhongguo Yao Li Xue Bao; 1994 May; 15(3):275-9. PubMed ID: 7976387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.